argenx is a global immunology company committed to improving lives of people suffering from severe autoimmune diseases. The Company developed and is commercializing the first approved neonatal Fc receptor blocker in the U.S., Japan, Israel, EU, UK, Canada and China and advancing its autoimmune pipeline across multiple serious autoimmune diseases.